The Biology and Treatment of Myelodysplastic Syndrome

Hematology/Oncology Clinics of North America

Volumn 24, Issue 2, 2010, Pages

  Ebert, Benjamin L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CBL PROTEIN; CLOFARABINE; CLORETAZINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DEATH ASSOCIATED PROTEIN KINASE; EZATIOSTAT; GLUTATHIONE TRANSFERASE; JANUS KINASE 2; LENALIDOMIDE; PROTEIN P53; TIPIFARNIB; UNCLASSIFIED DRUG; NEW DRUG;

ANEMIA; BONE MARROW TRANSPLANTATION; CHROMOSOME 5Q; CHROMOSOME DELETION; CLINICAL TRIAL; DNA METHYLATION; DRUG EFFICACY; EDITORIAL; EPIGENETICS; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LEUKOPENIA; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RELAPSE; REMISSION; SURVIVAL RATE; THROMBOCYTOPENIA; CHROMOSOME ABERRATION; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; MUTATION;

AZACITIDINE; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATIONS; DRUGS, INVESTIGATIONAL; EPIGENESIS, GENETIC; HUMANS; MUTATION; MYELODYSPLASTIC SYNDROMES;

EID: 77950540879     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.02.014     Document Type: Editorial

References (22)

1. Ma X., Does M., Raza A., et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007, 109:1536-1542.
2. Guralnik J., Eisenstaedt R., Ferrucci L., et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004, 104:2263-2268.
3. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
4. Kantarjian H., Issa J.P., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
5. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
6. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
7. Nachtkamp K., Kundgen A., Strupp C., et al. Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 2009, 33:1024-1028.
8. Alyea E.P., Kim H.T., Ho V., et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006, 12:1047-1055.
9. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006, 108:836-846.
10. Haase D., Germing U., Schanz J., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
11. Ebert B.L., Pretz J., Bosco J., et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008, 451:335-339.
12. Ebert B.L. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 2009, 23:1252-1256.
13. Lyons J., Janssen J.W., Bartram C., et al. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. Blood 1988, 71:1707-1712.
14. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001, 19:1405-1413.
15. Hellstrom-Lindberg E., Cazzola M. The role of JAK2 mutations in RARS and other MDS. Hematology Am Soc Hematol Educ Program 2008, 52-59.
16. Song W.J., Sullivan M.G., Legare R.D., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999, 23:166-175.
17. Harada H., Harada Y., Tanaka H., et al. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 2003, 101:673-680.
18. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 2004, 104:1474-1481.
19. Sanada M., Suzuki T., Shih L.Y., et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009, 460:904-908.
20. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
21. Gelsi-Boyer V., Trouplin V., Adelaide J., et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009, 145:788-800.
22. Boultwood J., Wainscoat J.S. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007, 138:3-11.